This trial will test if it is safe to use donor-derived CAR T cells to treat adults with B-cell ALL.
2 Primary · 5 Secondary · Reporting Duration: 1 year
Experimental Treatment
18 Total Participants · 2 Treatment Groups
Primary Treatment: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR) · No Placebo Group · Phase 1
Age 18 - 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: